These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 33470138)

  • 1. Estimation of the value of convenience in taking influenza antivirals in Japanese adult patients between baloxavir marboxil and neuraminidase inhibitors using a conjoint analysis.
    Hosogaya N; Takazono T; Yokomasu A; Hiroi S; Ikeoka H; Iwasaki K; Takeshima T; Mukae H
    J Med Econ; 2021; 24(1):244-254. PubMed ID: 33470138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Inconvenience Costs Between Influenza Antivirals for Japanese Pediatric Patients: A Conjoint Analysis of Parental Responses.
    Kurazono K; Ikeoka H; Hiroi S; Iwasaki K; Takeshima T; Tamura D
    Adv Ther; 2022 Apr; 39(4):1724-1742. PubMed ID: 35190996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimation of the cost of influenza antiviral medication guidance or support provided by healthcare professionals: a questionnaire survey in Japan.
    Kurazono K; Ikeoka H; Hiroi S; Iwasaki K; Takeshima T; Akazawa M
    J Med Econ; 2022; 25(1):38-50. PubMed ID: 34842029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Comparison of the Frequency of Prescription and Pharmacy Revisits between Baloxavir Marboxil and Neuraminidase Inhibitors in Influenza-Infected Pediatric Patients during the 2019-2020 Influenza Season.
    Norikoshi Y; Ikeda T; Sasahara K; Hamada M; Torigoe E; Nagae M; Tashiro T; Horio F; Saruwatari J; Uchida Y; Anraku M
    Biol Pharm Bull; 2020; 43(12):1960-1965. PubMed ID: 33268716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of baloxavir marboxil compared with laninamivir for the treatment of influenza in patients at high risk for complications in Japan.
    Dronova M; Ikeoka H; Itsumura N; Hirotsu N; Ansaripour A; Aballéa S; Onishi Y; Hill M; Igarashi A
    Curr Med Res Opin; 2021 Jul; 37(7):1135-1148. PubMed ID: 33858277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of baloxavir marboxil versus neuraminidase inhibitors in the treatment of influenza virus infection in high-risk and uncomplicated patients - a Bayesian network meta-analysis.
    Taieb V; Ikeoka H; Wojciechowski P; Jablonska K; Aballea S; Hill M; Hirotsu N
    Curr Med Res Opin; 2021 Feb; 37(2):225-244. PubMed ID: 33079575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A network meta-analysis of the efficacy and safety of baloxavir marboxil versus neuraminidase inhibitors for the treatment of influenza in otherwise healthy patients].
    Taieb V; Ikeoka H; Ma F; Borkowska K; Aballea S; Tone K; Hirotsu N
    Ter Arkh; 2020 Dec; 92(11):122-131. PubMed ID: 33720617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Household Transmission of Influenza Virus From Index Patients Treated With Baloxavir Marboxil or Neuraminidase Inhibitors: A Health Insurance Claims Database Study.
    Komeda T; Takazono T; Hosogaya N; Ogura E; Fujiwara M; Miyauchi H; Ajisawa Y; Iwata S; Watanabe H; Honda K; Kitanishi Y; Hara K; Mukae H
    Clin Infect Dis; 2021 Jun; 72(11):e859-e867. PubMed ID: 33103200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial.
    Kumar D; Ison MG; Mira JP; Welte T; Hwan Ha J; Hui DS; Zhong N; Saito T; Katugampola L; Collinson N; Williams S; Wildum S; Ackrill A; Clinch B; Lee N
    Lancet Infect Dis; 2022 May; 22(5):718-730. PubMed ID: 35085510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baloxavir Marboxil 2% Granules in Japanese Children With Influenza: An Open-label Phase 3 Study.
    Yokoyama T; Sakaguchi H; Ishibashi T; Shishido T; Piedra PA; Sato C; Tsuchiya K; Uehara T
    Pediatr Infect Dis J; 2020 Aug; 39(8):706-712. PubMed ID: 32433222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and virological outcomes with baloxavir compared with oseltamivir in pediatric patients aged 6 to < 12 years with influenza: an open-label, randomized, active-controlled trial protocol.
    Ishiguro N; Morioka I; Nakano T; Furukawa M; Tanaka S; Kinoshita M; Manabe A
    BMC Infect Dis; 2021 Aug; 21(1):777. PubMed ID: 34372769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virological and clinical outcomes in outpatients treated with baloxavir or oseltamivir: A Japanese multicenter study in the 2019-2020 influenza season.
    Chong Y; Kawai N; Tani N; Bando T; Takasaki Y; Shindo S; Ikematsu H
    Antiviral Res; 2021 Aug; 192():105092. PubMed ID: 34052230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Hospitalization Incidence in Influenza Outpatients Treated With Baloxavir Marboxil or Neuraminidase Inhibitors: A Health Insurance Claims Database Study.
    Komeda T; Takazono T; Hosogaya N; Miyazaki T; Ogura E; Iwata S; Miyauchi H; Honda K; Fujiwara M; Ajisawa Y; Watanabe H; Kitanishi Y; Hara K; Mukae H
    Clin Infect Dis; 2021 Sep; 73(5):e1181-e1190. PubMed ID: 33354728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baloxavir for the treatment of Influenza in allogeneic hematopoietic stem cell transplant recipients previously treated with oseltamivir.
    Salvatore M; Laplante JM; Soave R; Orfali N; Plate M; van Besien K; St George K
    Transpl Infect Dis; 2020 Aug; 22(4):e13336. PubMed ID: 32449254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baloxavir: A Novel Antiviral Agent in the Treatment of Influenza.
    Abraham GM; Morton JB; Saravolatz LD
    Clin Infect Dis; 2020 Oct; 71(7):1790-1794. PubMed ID: 32020174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Duration of fever and symptoms in children after treatment with baloxavir marboxil and oseltamivir during the 2018-2019 season and detection of variant influenza a viruses with polymerase acidic subunit substitutions.
    Saito R; Osada H; Wagatsuma K; Chon I; Sato I; Kawashima T; Saito T; Kodo N; Ono Y; Shimada Y; Phyu W; Shobugawa Y
    Antiviral Res; 2020 Nov; 183():104951. PubMed ID: 32987032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early combination treatment with baloxavir and peramivir for hospitalized adults with influenza A in Yokohama, Japan.
    Yoshimura Y; Sasaki H; Horiuchi H; Miyata N; Kawakami C; Usuku S; Tachikawa N
    Eur J Clin Microbiol Infect Dis; 2020 Sep; 39(9):1637-1640. PubMed ID: 32291543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baloxavir Marboxil Single-dose Treatment in Influenza-infected Children: A Randomized, Double-blind, Active Controlled Phase 3 Safety and Efficacy Trial (miniSTONE-2).
    Baker J; Block SL; Matharu B; Burleigh Macutkiewicz L; Wildum S; Dimonaco S; Collinson N; Clinch B; Piedra PA
    Pediatr Infect Dis J; 2020 Aug; 39(8):700-705. PubMed ID: 32516282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of Variants With Reduced Baloxavir Marboxil Susceptibility After Treatment of Children With Influenza A During the 2018-2019 Influenza Season.
    Sato M; Takashita E; Katayose M; Nemoto K; Sakai N; Hashimoto K; Hosoya M
    J Infect Dis; 2020 Jun; 222(1):121-125. PubMed ID: 32034420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuraminidase inhibitors and single dose baloxavir are effective and safe in uncomplicated influenza: a meta-analysis of randomized controlled trials.
    Tejada S; Tejo AM; Peña-López Y; Forero CG; Corbella X; Rello J
    Expert Rev Clin Pharmacol; 2021 Jul; 14(7):901-918. PubMed ID: 33861168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.